No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TNDM240517C37500
- 7.47
- -0.73-8.90%
15min DelayClose May 13 15:58 ET
7.80High7.47Low
7.80Open8.20Pre Close7 Volume88 Open Interest37.50Strike Price5.36KTurnover131.26%IV0.73%PremiumMay 17, 2024Expiry Date6.43Intrinsic Value100Multiplier3DDays to Expiry1.04Time Value100Contract SizeAmericanOptions Type0.8974Delta0.0308Gamma6.51Leverage Ratio-0.1391Theta0.0033Rho5.84Eff Leverage0.0079Vega
Intraday
- 5D
- 1D
News
Express News | Tandem Diabetes Care Recalls Version 2.7 Of Apple iOS T:Connect Mobile App Used With T:Slim X2 Insulin Pump With Control-IQ Technology
Express News | FDA: Tandem Diabetes Care Recall of Version 2.7 of Apple iOS T:Connect Mobile App Is a Correction, Not a Product Removal
Express News | FDA: Tandem Diabetes Care Recall of Version 2.7 of Apple iOS T:Connect Mobile App Prompted by Software Problem Leading to Pump Battery Depletion
Express News | FDA: Tandem Diabetes Care Recalls Version 2.7 of Apple iOS T:Connect Mobile App Used With T:Slim X2 Insulin Pump With Control-Iq Technology
Research Alert: CFRA Keeps Hold Opinion On Shares Of Tandem Diabetes Care, Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target price to $48 from $36
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Tandem Diabetes Care Is Maintained at Overweight by Barclays
Comments
Despite losses and negative cash flow, the company's US$178.2m balance sheet allows for at least two years of growth spending. However, the stock is seen as risky due to these financial conditions.
Is Tandem Diabetes Care (NASDAQ:TNDM) Using Debt In A Risky Way? 1
Tandem Diabetes Care's share price rise sparks hope, but turnarounds can be risky. The gap between revenue and share price growth could warrant further investigation. Last year's performance suggests unresolved issues, as it underperformed the annualised 10% loss over the past five years.
The stock is undervalued, indicating a potential buy opportunity. The company's positive future outlook and expected earnings increase aren't fully reflected in the current share price. Consider the company's financial health as well.
Despite the good rate of top-line growth at Tandem Diabetes Care, the severe share price drop indicates the company's losses might be larger than expected. Given the stock's past poor performance, there may be unresolved challenges the company is facing.
Analysts from Citi and Barclays revised their price targets for TNDM following reduced full-year revenue guidance despite strong Q3 results. Citi's Joanne Wuensch reduced her target from $23 to $18, while Barclays' Matt Miksic, citing poor international sales, lowered his target from $62 to $39.
Read more